Fatty Acid Inhibitor Treatment in Bipolar Depression
Principal Investigator: Rodrigo Machado-Vieira, MD, PhD, MSc
Study Contact
Name: Courtney Vecera
Email Address: [email protected]
Phone number: 713-486-2623
This study is currently looking for people who:
- Are 18 to 60 years old
- Have bipolar disorder and currently experiencing depression
- Taking a mood stabilizer
Study Description:
The purpose of this study is to investigate a new potential antidepressant called palmitoylethanolamide (PEA) alongside a mood stabilizer in patients with bipolar disorder. Eligible participants will receive a clinical evaluation, daily treatment with refills free of charge, and regular follow ups with the study team. You will be asked questions about your mood, anxiety, depression, other medical conditions and drug use. Some visits can be completed virtually for your convenience.
PEA is not a medication, it is considered a nutraceutical (combination of nutrition and pharmaceutical) that works by targeting the endocannabinoid system to reduce inflammation and may help reduce symptoms of depression.
All participants will be compensated for their time.